Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics

References

• Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PloS One 2015;10:1-14
   Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007;64:543-52
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. Washington, DC: American Psychiatric Publishing, 2013
   Google Scholar
• Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord 2014;169:S3-S11
   PubMed Web of Science ®Google Scholar
• Dilsaver SC, Chen Y-W, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997;73:47-56
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63:120-5
   PubMed Web of Science ®Google Scholar
• Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010;12:1-9
   PubMed Web of Science ®Google Scholar
• Latalova K, Kamaradova D, Prasko J. Suicide in bipolar disorder: a review. Psychiatr Danub 2014;26:108-14
   PubMed Web of Science ®Google Scholar
• Stensland MD, Zhu B, Ascher-Svanum H, et al. Costs associated with attempted suicide among individuals with bipolar disorder. J Ment Health Policy Econ 2010;13:87-92
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14
   PubMed Web of Science ®Google Scholar
• Kleine-Budde K, Touil E, Moock J, et al. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 2014;16:337-53
   PubMed Web of Science ®Google Scholar
• Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry 2003;160:1286-90
   PubMed Web of Science ®Google Scholar
• Fingar K, Washington R. Trends in Hospital Readmissions for Four High-Volume Conditions, 2009–2013: Statistical Brief #196. Rockville, MD: Agency for Healthcare Research and Quality (US), 2006. Available at: http://www.ncbi.nlm.nih.gov/books/NBK338299/ [Last accessed 28 March 2017]
   Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44
   PubMed Web of Science ®Google Scholar
• Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381:1672-82
   PubMed Web of Science ®Google Scholar
• Hirschfeld R. Bipolar depression: the real challenge. Eur Neuropsychopharmacol 2004;14:S83-S8
   PubMed Web of Science ®Google Scholar
• Franklin R, Zorowitz S, Corse AK, et al. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatr Dis Treat 2015;11:2143-52
   PubMed Web of Science ®Google Scholar
• Grande I, Bernardo M, Bobes J, et al. Antipsychotic switching in bipolar disorders: a systematic review. Int J Neuropsychopharmacol 2014;17:497-507
   PubMed Web of Science ®Google Scholar
• United States Congress. Health Insurance Portability and Accountability Act of 1996. 104-191 Aug 21, 1996. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-104publ191/html/PLAW-104publ191.htm
   Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
   PubMed Web of Science ®Google Scholar
• Faries DE, Leon AC, Haro JM, et al. Chapter 9. Analysis of Longitudinal Observational Data Using Marginal Structural Models. Anal Obs Health Care Data Using SAS. Cary, NC: SAS Institute Inc., 2010
   Google Scholar
• Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;550-60
   PubMed Web of Science ®Google Scholar
• Tunis SL, Ascher-Svanum H, Stensland M, et al. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. PharmacoEconomics 2004;22:1-8
   PubMed Web of Science ®Google Scholar
• Hedman LC, Petrila J, Fisher WH, et al. State laws on emergency holds for mental health stabilization. Psychiatr Serv 2016;67:529-35
   PubMed Web of Science ®Google Scholar
• Fewell Z, Hernán MA, Wolfe F, et al. Controlling for time-dependent confounding using marginal structural models. Stata J 2004;4:402-20
   Web of Science ®Google Scholar
• Gianfrancesco F, Rajagopalan K, Goldberg JF, et al. Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. Bipolar Disord 2007;9:252-61
   PubMed Web of Science ®Google Scholar
• Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001;3:181-8
   PubMed Web of Science ®Google Scholar
• Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci 2015;17:181-90
   PubMed Web of Science ®Google Scholar
• Rosa AR, Reinares M, Franco C, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord 2009;11:401-9
   PubMed Web of Science ®Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr 2004;9:6-14
   PubMed Web of Science ®Google Scholar
• Tohen M, Ng-Mak D, Rajagopalan K, et al. Patient characteristics associated with use of lurasidone versus other atypical antipsychotics in patients with bipolar disorder: analysis from a claims database in the United States. Prim Care Companion CNS Disord 2017;19:0-0
   Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-33
   PubMed Web of Science ®Google Scholar
• Meyer JM, Ng-Mak DS, Chuang C-C, et al. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry 2017;16:36
   PubMed Web of Science ®Google Scholar
• Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014;13:1163-91
   PubMed Web of Science ®Google Scholar
• Citrome L, Kalsekar I, Guo Z, et al. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis. Clin Ther 2013;35:1867-75
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Kenna GA. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health-Syst Pharm 2008;65:611-18
   PubMed Web of Science ®Google Scholar
• Sperber CM, Samarasinghe SR, Lomax GP. An upper and lower bound of the Medication Possession Ratio. Patient Prefer Adherence 2017;11:1469-78
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Wade S, Chu B-C, et al. Adherence to lurasidone and other atypical antipsychotics among patients with bipolar disorder: a real world assessment. J Health Med Econ 2016;2:1-10
   Google Scholar
• Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry 2009;8:7
   PubMedGoogle Scholar
• Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord 2014;169:S34-44
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Meyer K, O’Day K, et al. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression. J Med Econ 2015;18:821-7
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy 2015;35:813-22
   PubMed Web of Science ®Google Scholar
• Stensland M, Watson PR, Grazier KL. An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. Psychiatr Serv 2012;63:666-71
   PubMed Web of Science ®Google Scholar